Trials / Terminated
TerminatedNCT00050336
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 702 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the overall survival of patients diagnosed with Stage 3b or 4 non-small cell lung cancer (NSCLC) treated with an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 66336) in combination with paclitaxel and carboplatin with that of patients treated with placebo in combination with paclitaxel and carboplatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lonafarnib (SARASAR) |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2004-02-01
- Completion
- 2004-03-01
- First posted
- 2002-12-05
- Last updated
- 2015-08-27
Source: ClinicalTrials.gov record NCT00050336. Inclusion in this directory is not an endorsement.